Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$94.35 USD

94.35
239,975

+0.59 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.

Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View

Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y

Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.

Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Microbot Medical (MBOT) Announces Positive GLP Study Results

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?

Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.

MMSI or WST: Which Is the Better Value Stock Right Now?

MMSI vs. WST: Which Stock Is the Better Value Option?